Analytical Data
-
Gene name
CHRNa9
- Application
-
Alternative Names
CHRNa9；NACHRA9；Neuronal acetylcholine receptor subunit alpha-9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UGM1
-
Expression Region
1-479aa
-
AA Sequence
MNWSHSCISFCWIYFAASRLRAAETADGKYAQKLFNDLFEDYSNALRPVEDTDKVLNVTLQITLSQIKDMDERNQILTAYLWIRQIWHDAYLTWDRDQYDGLDSIRIPSDLVWRPDIVLYNKADDESSEPVNTNVVLRYDGLITWDAPAITKSSCVVDVTYFPFDNQQCNLTFGSWTYNGNQVDIFNALDSGDLSDFIEDVEWEVHGMPAVKNVISYGCCSEPYPDVTFTLLLKRRSSFYIVNLLIPCVLISFLAPLSFYLPAASGEKVSLGVTILLAMTVFQLMVAEIMPASENVPLIGKYYIATMALITASTALTIMVMNIHFCGAEARPVPHWARVVILKYMSRVLFVYDVGESCLSPHHSRERDHLTKVYSKLPESNLKAARNKDLSRKKDMNKRLKNDLGCQGKNPQEAESYCAQYKVLTRNIEYIAKCLKDHKATNSKGSEWKKVAKVIDRFFMWIFFIMVFVMTILIIARAD
-
Molecular Weight
54.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on recombinant CHRNA9 protein has gained significant attention due to its crucial role in the physiology of the nervous system and its potential implications in various neurological disorders. CHRNA9 encodes the alpha-9 nicotinic acetylcholine receptor (nAChR), which is primarily expressed in cochlear hair cells and certain neurons, playing a vital role in auditory processing and cholinergic signaling. Dysregulation of CHRNA9 expression and function has been linked to several conditions, including auditory nerve damage and cancer, highlighting its importance in both sensory biology and pathophysiology. Additionally, the CHRNA9 protein is a promising target for developing therapeutic interventions aimed at chronic pain and neurodegenerative diseases. Recombinant CHRNA9 protein studies involve the expression and purification of this receptor to investigate its functional properties, pharmacological profiles, and interactions with various ligands and drugs. Understanding the structural and biochemical characteristics of the CHRNA9 receptor through recombinant technologies can pave the way for novel strategies to modulate its activity, potentially leading to innovative treatments for auditory and neurological disorders. As research progresses, the elucidation of the mechanisms underlying CHRNA9’s function and regulation holds promise for unlocking new avenues in both basic and applied biomedical sciences.
